Invitrx Therapeutics

American Peptide Company offers a vast range of pharmaceutical-grade peptides, as well as products and services for protein research applications. It features Boc/Fmoc amino acid derivatives and resins for custom peptide synthesis. The company s capabilities include peptide-protein conjugation, quantities to kilograms, multiple disulfide bridges, complex peptides, peptidomimetics and specialty amino acids and derivatives. APC s scientists are experienced with phosphorylated and biotinylated structures, chromogenic and fluorogenic substrates, process development and solid-phase, solution and segment coupling technologies. The company s FDA-licensed cGMP facilities are designed for large-scale manufacturing of pharmaceutical drug substances for clinical research. American Peptide Company is a subsidiary of Itoham Foods and is based in Sunnyvale, Calif.

NantWorks LLC, based in Culver City, is dedicated to solving global problems through innovative approaches and technologies. With a focus on cutting-edge solutions, the company aims to make a positive impact on a global scale. By leveraging innovative technologies, NantWorks LLC is committed to addressing complex challenges and driving positive change worldwide. Their forward-thinking approach sets them apart as leaders in the field of problem-solving and innovation. Generated from their website's infomation

BioTime is engaged in the research and development of aqueous-based synthetic solutions that may be used for blood plasma expansion, blood replacement and organ preservation solutions. The company s patented products are intended for a number of uses, including treatment of hypovolemia, emergency blood replacement, blood transfusions, neurosurgery and the preservation of organs and tissues waiting for transplant. BioTime's products are manufactured and distributed in the United States and Canada by Hospira, and in the Republic of Korea by CJ Corp under an exclusive licensing agreement. BioTime moved to its new headquarters in Emeryville, Calif., in 2005.